[November 10, 2009] xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 10, 2009 : DWA, PCTI, AVNR and JMBA Tweet Nov 10, 2009 (M2 PRESSWIRE via COMTEX) -- Xtremepicks.com Alerts include DreamWorks Animation SKG, Inc. (Nasdaq: DWA), PCTEL, Inc. (NASDAQ: PCTI), AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) and Jamba, Inc. (NASDAQ: JMBA) DreamWorks Animation SKG, Inc. (Nasdaq: DWA) trading at $33.45 on a volume of 238,030 shares In a press release out on November 10, DreamWorks Animation Names Andrew Chang General Counsel GLENDALE, Calif., Nov 10, 2009 -- DreamWorks Animation SKG, Inc. (Nasdaq: DWA) today announced that Andrew Chang, DreamWorks Animation's Head of Litigation and Technology Law, has been named General Counsel. About DreamWorks Animation DreamWorks Animation creates high-quality entertainment, including CG animated feature films, television specials and series, live entertainment properties and online virtual worlds, meant for audiences around the world. The Company has world-class creative talent, a strong and experienced management team and advanced filmmaking technology and techniques. All of DreamWorks Animation's feature films are now being produced in 3D. The Company has theatrically released a total of 18 animated feature films, including the franchise properties "Shrek," "Madagascar" and "Kung Fu Panda." PCTEL, Inc. (NASDAQ: PCTI) trading at $5.67 per share on trading volume of 11,550 shares. In a press release out on November 10, PCTEL and Wider Networks Settle Intellectual Property Dispute PCTEL Becomes Exclusive Distributor of Wider Products and Acquires Wider's Patent Portfolio BLOOMINGDALE, Ill., Nov 10, 2009 -- PCTEL, Inc. (NASDAQ: PCTI), a leader in propagation and wireless network optimization solutions, announced today that it has settled its intellectual property dispute with Wider Networks. Under the terms of the agreement, PCTEL has acquired the two patents underlying Wider Networks' products. PCTEL also acquired exclusive distribution rights to Wider's product portfolio and will incorporate Wider's products into PCTEL's product portfolio. About PCTEL PCTEL, Inc. (NASDAQ: PCTI), is a global leader in propagation and wireless network optimization solutions. The company designs and develops software-based radios for wireless network optimization and develops and distributes innovative antenna solutions. The company's SeeGull(R) scanning receivers, receiver-based products and CLARIFY(R) interference management solutions are used to measure, monitor and optimize cellular networks. PCTEL's SeeGull scanning receivers are deployed in industry leading wireless test and measurement equipment and viewed as an essential wireless data collection tool for cellular network optimization, drive tests, and spectrum clearing. PCTEL develops and supports scanning receivers for LTE, EVDO, CDMA, WCDMA, UMTS, TDS-CDMA and WiMAX networks. AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) trading at $1.91 on a volume of 1.10M shares In a press release out on November 10, Avanir Pharmaceuticals Announces Zenvia Safety and Efficacy Data from Star Trial Open Label Extension ALISO VIEJO, Calif., Nov 10, 2009 -- AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia(TM) (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA). ABOUT AVANIR AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva(R) (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org. Jamba, Inc. (NASDAQ: JMBA) trading at $1.73 on a volume of 149,234 shares In a press release out on November 10, Jamba Juice Promotes Susan Shields to Chief Marketing Officer EMERYVILLE, Calif., Nov 10, 2009 -- Jamba, Inc. (NASDAQ: JMBA) today announced the promotion of veteran marketer Susan Shields to Senior Vice President and Chief Marketing Officer, Jamba Juice Company. She will join the Jamba Juice executive leadership team reporting directly to James D. White, President and Chief Executive Officer, Jamba Juice Company. About Jamba, Inc. Jamba, Inc. (NASDAQ: JMBA) is a holding company and through its wholly-owned subsidiary, Jamba Juice Company, owns and franchises JAMBA JUICE(R) stores. Founded in 1990, Jamba Juice is a leading restaurant retailer of better-for-you food and beverage offerings, including great tasting fruit smoothies, juices, and teas, hot oatmeal made with organic steel cut oats, wraps, salads, sandwiches, and California Flatbreads(TM), and a variety of baked goods and snacks. As of October 6, 2009, Jamba Juice had 742 locations consisting of 488 company-owned and operated stores and 254 franchise stores. For the nearest location or a complete menu, visit the Jamba Juice website at www.jambajuice.com or call 1-866-4R-FRUIT. Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience. Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at [email protected] Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm CONTACT: Xtremepicks.com e-mail: [email protected] WWW: http://www.Xtremepicks.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. [ Back To TMCnet.com's Homepage ]